



Transforming Organ Transplantation Therapy Worldwide

October 2024



Cautionary Note Regarding Forward-Looking Statements


This presentation contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance. Investors are cautioned not to place undue reliance on these forward-looking statements. For this purpose, all statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy and plans and our objectives for future operations are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System ("OCS"); our ability to expand access to OCS through our National OCS Program ("NOP"); our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors of benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States, the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration ("FDA"), or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and to reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration ("FAA") or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. These forward-looking statements in this presentation speak only as of the date of this presentation. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Market & Industry Data

Projections, estimates, industry data and information contained in this presentation, including the Company's general expectations and market position and market opportunity, are based on information from third-party sources and management estimates. Although the Company believes that its third-party sources are reliable, the Company cannot guarantee the accuracy or completeness of its sources. The Company's management estimates are derived from third-party sources, publicly available information, the Company's knowledge of its industry and assumptions based on such information and knowledge. The Company's management estimates have not been verified by any independent source. All of the projections, estimates, market data and industry information used in this presentation involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such information. In addition, projections, estimates and assumptions relating to the Company's and its industry's future performance and the Company's estimates of the potential pool of donors and potential addressable commercial opportunity, are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including, but not limited to, those described above, that could cause future performance to differ materially from the Company's expressed projections, estimates and assumptions or those provided by third parties.



Transplant Challenges - Massive Underutilization of Donor Organs for Transplants



Source: 2023 OPTN US National Data



The Only FDA-Approved Multi-Organ Technology Platform



Historical Logistics Challenges Led to Lost Transplant Missions, Added Costs & Delays

Plane availability - Current brokers don't own/control jets leading to loss of missions

Pilots' time-out and unexpected plane repositioning could double or triple the cost

Inefficient round-trip logistics model for DBD and DCD donors adds unnecessary costs

NOPT™ Provides End-to-End OCST™ Technology & Clinical Services to Transplant Centers in the U.S.




Enable programs' growth without historical time and distance limitations

Reduce learning curves & ensure consistent high clinical standards of Mgmt.


Optimal Mgmt. of programs' clinical/financial resources & work-life balance for teams

NOP Hubs to Provide Broad Geographical Coverage



TMDX Volume Growth - Heart, Lung & Liver Transplants



> 130% Growth




8 *Number of transplants performed using the OCS or with NOP




U.S. National Volume Growth - Heart & Liver Transplants



Improved Clinical Outcomes with NOP



~50% Reduction in Night-Time Transplants





Building a dedicated fleet of modern jets & dedicated pilot crew to cover NOP missions



Operated with highest safety rating in the industry – “*Argus Platinum Elite*”



Maintain **24/7/365** operational availability



Maximizing & sharing cost efficiencies with Tx. programs



Currently Operating Fleet of
18 Dedicated Jets



TMDX NOP Digital Logistics Command Center



Overall Impact of NOP Model in the U.S.

Expand the access and utilization of DBD and DCD donors

Grow your transplant volume without added fixed cost of resources

Enables day time transplants

Transforming Standard of Care

Grow the overall national transplant volume


Superior clinical outcomes

Significant cost savings

Financial Highlights


Quarterly Revenue

\$ millions



Annual Revenue

\$ millions




Financial Overview

- Continued growth driven by increased utilization of OCS across all three organs through the NOP
- \$330.1 Million Cash Balance as of September 30, 2024



TMDX Growth Strategy

Enabling Transplant Volume Growth Through Innovation & Expansion



TMDX Unique Competitive Advantage

BROAD INDICATIONS

Multiple Approved FDA PMAs with Broad DBD and DCD indications

TECHNOLOGY

Technology Customized to Fit in and Optimize Current Workflow

IP

>400 Issued Patents and Pending Patent Applications Worldwide*

NATIONAL OCS PROGRAM (NOP)

Streamline the Process of Organ Transplantation in U.S.

VERSATILE


The Only FDA Approved Multi-Organ Platform

CLINICAL EVIDENCE

Established Body of Global Clinical Evidence

GLOBAL PRESENCE

Established Presence at Leading Global Academic Transplant Centers





Shaping the Future of Organ Transplantation